Two parallel randomized phase II studies of selumetinib (S) and erlotinib (E) in advanced non-small cell lung cancer selected by KRAS mutations.
Corey Allan Carter
No relevant relationships to disclose
Arun Rajan
No relevant relationships to disclose
Eva Szabo
No relevant relationships to disclose
Sean Khozin
No relevant relationships to disclose
Anish Thomas
No relevant relationships to disclose
Christina E. Brzezniak
No relevant relationships to disclose
Udayan Guha
No relevant relationships to disclose
L. Austin Doyle
No relevant relationships to disclose
Corrine Keen
No relevant relationships to disclose
Seth M. Steinberg
No relevant relationships to disclose
Liqiang Xi
No relevant relationships to disclose
Mark Raffeld
No relevant relationships to disclose
Karen L. Reckamp
No relevant relationships to disclose
Stephen Koehler
No relevant relationships to disclose
Barbara Jennifer Gitlitz
No relevant relationships to disclose
Ravi Salgia
No relevant relationships to disclose
David R. Gandara
No relevant relationships to disclose
Everett E. Vokes
No relevant relationships to disclose
Giuseppe Giaccone
No relevant relationships to disclose